BioSpace News Archive

magAssist Inc. attended the 2022 Critical Heart Disease Congress - International Society for Mechanical Circulatory Support Parallel Forum, where the firm shared the latest research results and technologies for the treatment of critical heart diseases with fellow cardiovascular researchers and experts, demonstrating its commitment to innovation and development in the field.

Driven by the Covid-19 pandemic, the market for point-of-care testing is seen to double in size compared to pre-pandemic levels.

Sirona Biochem Corp. announces the termination of the Rodan + Fields agreement for supply and use of TFC-1067 in commercial formulations.

FAPON announced that Mr. Jielun ZHU, the company’s Chief Financial Officer (CFO) and Chief Investment Officer (CIO), has presented at the 41st Annual J.P. Morgan Healthcare Conference and shared FAPON’s development, achievements and future plans in life sciences.

PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (“PsyBio” or the “Company”), an intellectual property driven biotechnology company focused upon discovery and development of novel psycho-targeted therapeutics

The Barbara Ann Karmanos Cancer Institute kicks off year two of its “Inspired” campaign, inviting the community to view a cancer diagnosis not as an ending but as an opportunity to think bigger, think broader, think “Cancer is a Beginning.”

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (“Defence” or the “Company”), a Canadian biopharmaceuticals company primarily focussed on the development of novel immune-oncology vaccines and drug delivery technologies including Antibody Drug Conjugate

Pharmascience Canada launches the generic Prpms-TOFACITINIB in the Canadian market, last November 2022.

Meiji Seika Pharma Co., Ltd. and the Foundation for Biomedical Research and Innovation at Kobe announce the discovery of a novel anti-PD-1 agonist monoclonal antibody, which can induce immunosuppressive effect, through their collaborative research on “Treatment of inflammatory diseases, including autoimmune diseases, through the immunosuppressive activity of PD-1” conducted at the FBRI’s Dept. of Immunology, Institute of Biomedical Research and Innovation.

Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage biopharmaceutical company, announced that the China National Medical Products Administration (NMPA) has approved BAT1806, a biosimilar of Actemra ® (tocilizumab), in China.